Premium
Felbamate Urolithiasis
Author(s) -
Sparagana S. P.,
Strand W. R.,
Adams R. C.
Publication year - 2001
Publication title -
epilepsia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.687
H-Index - 191
eISSN - 1528-1167
pISSN - 0013-9580
DOI - 10.1046/j.1528-1157.2001.32500.x
Subject(s) - medicine , felbamate , urology , voiding cystourethrogram , lithotripsy , kidney stones , discontinuation , crystalluria , stent , cystoscopy , urinary system , surgery , anticonvulsant , calcium oxalate , disease , reflux , psychiatry , vesicoureteral reflux , epilepsy
Summary: Purpose: To report a case of felbamate (FBM) urolithiasis. Methods: Urographic imaging [sonography, abdominal computed tomography (CT), intravenous pyelogram, voiding cystourethrogram] and urologic procedures (cystoscopy with lithotripsy, ureteral stent) to define and capture the stones. Stone identification was by infrared spectroscopy and gas chromatography/mass spectrometry. Results: A 15‐year‐old boy had painful hematuria, bilateral ureteral obstruction, and urinary retention. Kidney, bladder, and ureteral stones were found, and ureteral stent placement was required to relieve obstruction. The stone material was identified as FBM by chemical analysis. Stone formation ceased with discontinuation of FBM. Conclusions: FBM urolithiasis can occur, and possible contributory factors include high felbamate dosage, drug polypharmacy, and risk factors for forming stones of other types. FBM urolithiasis may be heralded by crystalluria.